TMTakanori Morikawa

Takanori Morikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takanori Morikawa has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating Tumor DNA Across the Patient Journey in Pancreatic Cancer: From Molecular Profiling to Dynamic Disease Monitoring

    by Makoto Abue, Naoki Asano, Takanori Morikawa, Atsushi Masamune, Satoshi Nishizuka, Jun Yasuda

    Background/Objectives: Circulating tumor DNA (ctDNA) provides molecular information at different stages of the pancreatic ductal adenocarcinoma (PDAC) patient journey, but its clinical value differs according to when and why it is measured. This narrative review examines ctDNA from diagnosis and molecular profiling through neoadjuvant therapy, postoperative molecular residual disease (MRD), surveillance, and dynamic monitoring during systemic therapy, critically assessing the strength and limitations of the evidence at each clinical stage and its implications for clinical decision-making. Methods: Relevant studies were identified primarily through PubMed/MEDLINE, supplemented by forward citation tracking in Google Scholar, backward reference screening, and ClinicalTrials.gov searches for ongoing interventional studies. Original PDAC clinical studies were prioritized, with selected reviews, guidelines, consensus statements, and position papers used for context. Results: In localized disease, limited ctDNA shedding constrains diagnostic sensitivity, although baseline detection may provide prognostic information. After surgery, ctDNA positivity consistently identifies patients at increased risk of recurrence, whereas a negative result cannot reliably exclude residual disease. During surveillance, newly detectable or rising ctDNA may precede radiological recurrence. In advanced disease, serial ctDNA kinetics provide increasingly consistent information on treatment response and progression. Evidence for dynamic monitoring is increasing, but evidence that ctDNA-guided treatment or surveillance improves patient outcomes remains insufficient. Conclusions: The clinical value of ctDNA depends on when and why it is measured. ctDNA should complement rather than replace conventional assessments. By distinguishing established prognostic associations from emerging monitoring applications and unproven ctDNA-guided interventions, this review provides a practical framework for interpreting ctDNA across the PDAC patient journey. Prospective trials are needed to determine whether ctDNA-guided decisions improve patient outcomes.

  • Open Access

    Perioperative outcomes of older adult patients with pancreatic cancer based on nutritional status: a retrospective cohorat study

    by Takanori Morikawa, Masaharu Ishida, Masamichi Mizuma, Kei Nakagawa, Takashi Kamei, Michiaki Unno

    Purpose: This study investigated the effects of preoperative nutritional status on postoperative outcomes in older adult patients with pancreatic adenocarcinoma.Methods: The background and perioperative factors of patients who underwent pancreatectomy for pancreatic adenocarcinoma between 2007 and 2020 were retrospectively analyzed.Results: Patients aged 75 years or over (older adults) were significantly associated with hypertension, upfront surgery, and lower prognostic nutritional index. In addition, these patients had a significantly lower rate of portal vein resection, less blood loss, and shorter operation time than patients aged less than 75 years (non-older adults). During the postoperative course, older adult patients had a higher rate of pneumonia and lower overall survival than younger patients, although recurrence‐free survival was comparable. In addition, older adult patients showed preoperative malnutrition as a risk factor for postoperative in‐hospital death.Conclusion: Surgical treatment for pancreatic cancer in older adult patients was performed safely. However, preoperative malnutrition is a risk factor for in‐hospital death and such patients require nutritional support and less‐invasive surgery.


  • Open Access

    Current status and therapeutic strategy of acute acalculous cholecystitis: Japanese nationwide survey in the era of the Tokyo guidelines

    by Takanori Morikawa, Masanori Akada, Kenji Shimizu, Yasunori Nishida, Junko Izai, Hiroki Kajioka, Takayuki Miura, Masaharu Ishida, Michiaki Unno

    Purpose: This study aimed to clarify the incidence, therapeutic modality, and prognosis of acute acalculous cholecystitis and to reveal its optimal treatment strategy.Methods: As a project study of the Japanese Society for Abdominal Emergency Medicine, we performed a questionnaire survey of demographic data and perioperative outcomes of acute acalculous cholecystitis treated between January 2018 and December 2020 from 42 institutions.Results: In this study, 432 patients of acute acalculous cholecystitis, which accounts for 7.04% of acute cholecystitis, were collected. According to the Tokyo guidelines severity grade, 167 (38.6%), 202 (46.8%), and 63 (14.6%) cases were classified as Grade I, II, and III, respectively. A total of 11 (2.5%) patients died and myocardial infarction/congestive heart failure was the only independent risk factor for in‐hospital death. Cholecystectomy, especially the laparoscopic approach, had more preferable outcomes compared to their counterparts. The Tokyo guidelines flow charts were useful for Grade I and II severity, but in the cases with Grade III, upfront cholecystectomy could be suitable in some patients.Conclusions: The proportions of severity grade and mortality of acute acalculous cholecystitis were found to be similar to those of acute cholecystitis, and laparoscopic cholecystectomy is recommended as an effective treatment option. (UMIN000047631).


  • Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection

    by Tatsuo Hata, Masamichi Mizuma, Fuyuhiko Motoi, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Michiaki Unno

    Purpose: We aimed to clarify the prognostic impact of postoperative circulating tumor DNA (ctDNA) shortly after pancreatectomy in patients with pancreatic ductal adenocarcinoma (PDAC).Methods: Preoperative and paired postoperative blood samples were obtained from 66 patients in patients with PDAC. Cell‐free DNA was extracted from the plasma, and KRAS mutations, as a benchmark of ctDNA, were examined using droplet digital PCR. Disease‐free survival (DFS) and overall survival (OS) were compared between patients with presence and absence of ctDNA.Results: In univariate analysis, patients with detectable postoperative ctDNA showed worse survival than those with undetectable in both DFS (P = .034) and OS (P = .022). Multivariate analysis also revealed that the presence of postoperative ctDNA was an independent risk factor for recurrence (hazard ratio: 2.677, P = .011). In contrast, preoperative ctDNA detection did not affect long‐term outcomes. These trends persisted in 34 patients with resectable PDAC who underwent resection after neoadjuvant chemotherapy. Patients with detectable postoperative ctDNA were more prone to developing hepatic recurrence than those with undetectable postoperative ctDNA (P = .039).Conclusion: Postoperative ctDNA, as a minimal residual marker, can be useful for predicting the risk of recurrence in patients with PDAC even after curative resection.


  • Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer

    by Mitsuhiro Shimura, Masamichi Mizuma, Fuyuhiko Motoi, Akiko Kusaka, Shuichi Aoki, Masahiro Iseki, Koetsu Inoue, Daisuke Douchi, Shun Nakayama, Takayuki Miura, et al.


  • Open Access

    Levels of tumor markers CEA/CA 19–9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer

    by Tatsuo Hata, Kazuharu Chiba, Masamichi Mizuma, Kunihiro Masuda, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Hiroki Hayashi, Fuyuhiko Motoi, Michiaki Unno

    Aim: This study aimed to clarify the usefulness of tumor markers from peritoneal lavage in selecting patients with a high risk of recurrence and predicting site‐specific recurrence in patients with pancreatic cancer.Methods: The levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19–9 (sCEA/sCA 19–9) and paired peritoneal lavage CEA and CA 19–9 (pCEA/pCA 19–9) were measured in 90 patients with pancreatic cancer who underwent surgery. Using the cutoff values determined by maximally selected rank statistics for disease‐free survival (DFS), the risk of recurrence and its patterns were evaluated in combination with different markers and different test specimens.Results: In univariate and multivariate analysis, an elevated pCA 19–9 level (>1.3 U/mL) was an independent prognostic marker for both DFS (hazard ratio [HR], 2.391; P = .018) and overall survival (HR, 3.194; P = .033). Combination analyses contributed to further stratification of a very high risk of recurrence. Of the 58 patients with resectable pancreatic cancer who underwent curative resection, elevated pCA19–9 was also associated with inferior DFS and overall survival (OS). Patients with elevated pCA 19–9 levels were more likely to have an earlier onset of peritoneal recurrence than those with normal pCA 19–9 levels (P = .048, Gehan–Breslow–Wilcoxon test).Conclusion: pCA 19–9 is a reliable marker for predicting postoperative recurrence in patients with pancreatic cancer after surgery. Further risk stratification can be achieved by using combination assays. The combination of pCA 19–9 and sCA19–9 also serves as a predictor of recurrence site‐specific recurrence.


  • What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma?

    by Masahiro Iseki, Masamichi Mizuma, Shuichi Aoki, Kei Kawaguchi, Kunihiro Masuda, Masaharu Ishida, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Takashi Kamei, et al.


  • Laparoscopic and robot-assisted surgery for adult congenital biliary dilatation achieves favorable short-term outcomes without increasing the risk of late complications

    by Takanori Morikawa, Hideo Ohtsuka, Tatsuyuki Takadate, Masaharu Ishida, Takayuki Miura, Masamichi Mizuma, Kei Nakagawa, Takashi Kamei, Takeshi Naitoh, Michiaki Unno

    Purpose Minimally invasive surgery (MIS) is the optimal treatment for congenital biliary dilatation (CBD), but few studies on adults have been reported. We compared the postoperative outcomes of MIS with those of open surgery (OS) in adult patients with CBD. Methods The subjects of this retrospective study were 36 adult patients who underwent surgery for CBD. We compared the postoperative outcomes of 20 patients who underwent laparoscopic (n = 15) or robotic (n = 5) surgery with those of 16 patients who underwent OS. Results MIS was associated with a significantly higher rate of type I (p < 0.001), significantly less blood loss (p < 0.001), a significantly lower rate of internal stents (p = 0.048), significantly longer operation times (p = 0.009), and a significantly shorter postoperative hospital stay (p = 0.007) than OS. The postoperative outcomes of MIS for type I CBD were similar to those of the whole cohort. There were no significant differences in late complications between the groups. The robotic procedure had a significantly shorter operative time than laparoscopic surgery for hepaticojejunostomy (HJ; p = 0.029). Conclusions MIS achieved favorable short-term outcomes without compromising mid-term outcomes compared to OS and is appropriate for adult patients with CBD. Robotic HJ may be more ideal than its laparoscopic counterpart.


  • Open Access

    Perioperative outcomes of elderly patients with pancreatic cancer from the standpoint of nutritional status

    by Takanori Morikawa, Masaharu Ishida, Masamichi Mizuma, Kyouhei Ariake, Kei Kawaguchi, Kunihiro Masuda, Hideo Ohtsuka, Kei Nakagawa, Takashi Kamei, Michiaki Unno

    [目的]術前栄養学的指標の高齢者膵癌切除例の術後成績への影響について後方視的に検討した. [対象・方法]対象は2007年1月~2020年6月に切除術を行った膵癌症例549例, うち75歳以上の後期高齢者は122例であった. 栄養指標として小野寺のprognostic nutritional index (PNI) およびCONUT値を用いた. [結果]非後期高齢者と比較すると後期高齢者は, 高血圧併存例, 術前化学療法非施行例が有意に多く, PNIが有意に低値であった. 反面, 外科治療として膵尾側切除が多く, 門脈合併切除率, 手術時間, 出血量が有意に低値であった. 術後肺炎は後期高齢者が有意に多く, 全生存率も有意に低値であったが, 無再発生存率では差はなかった. 後期高齢者群のみで検討すると, PNIおよびCONUT値にて栄養障害を示す症例は, 在院死亡の危険因子であった. [結語]後期高齢者膵癌の外科治療は, 手術侵襲が軽減され, 安全に行われていた. しかし術前の栄養障害は在院死亡の危険因子であり, 栄養不良例は対策を講ずる必要がある.


  • Open Access

    Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population

    by Tatsuo Hata, Masamichi Mizuma, Fuyuhiko Motoi, Masaharu Ishida, Hideo Ohtsuka, Kei Nakagawa, Takanori Morikawa, Toru Furukawa, Michiaki Unno

    Aim: Cancer patients with personal/family histories of pancreatic/breast/ovarian/prostate cancer are associated with a higher likelihood of harboring DNA damage repair (DDR)‐related germline mutations. Here, we aimed to obtain a better understanding of DDR‐related germline mutations in Japanese pancreatic ductal adenocarcinoma (PDAC) patients with personal and/or family histories of BRCA‐related cancers of the pancreas, breast, ovary, and prostate.Methods: We performed next‐generation sequencing (NGS) and evaluated germline mutations in nine DDR‐related genes (BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, and PMS2) in PDAC patients with personal and/or family histories.Results: Of 196 patients with PDAC, 39 (19.9%) fulfilled the criteria for at least one family history of pancreatic/breast/ovarian/prostate cancer in first‐degree relatives (sibling–sibling or parent‐child) or the personal history of these malignancies. Targeted NGS revealed that four (10.2%) of 39 patients with personal/family histories harbored deleterious germline mutations—two in BRCA2, one in ATM, and one in MLH1. Both the BRCA2 variants showed frameshift mutations due to short insertion/deletions. In the 39 patients undergoing NGS, a similar distribution of the clinicopathological characteristics was observed between those with deleterious mutations/variants of unknown significance (VUSs) and with benign/wild types. Patients with deleterious germline mutations/VUSs in DDR‐related genes showed a significantly more favorable prognosis than those with benign mutations/wild‐type genes (hazard ratio: 0.160, P = .040).Conclusions: A significant fraction of PDAC patients with personal/family histories of BRCA‐related cancers harbored deleterious germline mutations in DDR‐related genes. DDR‐related germline gene mutations might be a favorable prognostic factor in patients with pancreatic cancer.